Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Managing Relapsed DLBCL

July 26th 2021

Cyrus Khan, MD, reviews the management of DLBCL after relapse on frontline therapy.

Brentuximab Vedotin Plus Chemo Shows Strong Activity in Early-Stage Hodgkin Lymphoma

July 25th 2021

The combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine with and without consolidative radiotherapy was found to have strong efficacy and favorable tolerability in patients with early-stage, unfavorable-risk, Hodgkin lymphoma.

Individualized Treatment for MDS

July 23rd 2021

The panel of leukemia experts highlight the importance of individualized treatments for patients with myelodysplastic syndrome.

Staging Models in Diagnosis and Risk Assessment of MDS

July 23rd 2021

Rami Komrokji, MD, and Gail Roboz, MD, discuss the importance of staging models in the diagnosis and routine assessment of patients with myelodysplastic syndrome.

Siddiqi Spotlights Latest Data on Optimization of Therapy in Hematologic Malignancies

July 23rd 2021

Data presented during the 2021 ASCO Annual Meeting offered insight into the optimization of BTK inhibitors, induction therapy, consolidative therapy, and radiation therapy for patients across the paradigm of hematologic malignancies.

Molecular Testing Turnaround Time and Treatment Delay

July 22nd 2021

Key opinion leaders in acute myeloid leukemia reflect on challenges associated with molecular testing by commenting on potential treatment delay from the long turnaround time (TAT) of next-generation sequencing.

Transplant-Associated Thrombotic Microangiopathy: New Insights, Emerging Treatments

July 22nd 2021

An expert of panelists provide an overview of TA-TMA, including findings that raise suspicion of this complication, strategies they use for making the diagnosis, and how they intervene given limited treatment options.

Molecular Testing for Acute Myeloid Leukemia

July 22nd 2021

Mark Levis, MD, PhD, leads a panel of experts in a discussion on factors to consider when ordering molecular testing for newly diagnosed and relapsed/refractory acute myeloid leukemia.

Dr. Sallman on the Efficacy of Pevonedistat Plus Azacitidine in Higher-Risk MDS

July 21st 2021

David Sallman, MD, discusses the efficacy of pevonedistat plus azacitidine in higher-risk myelodysplastic syndrome.

Dr. Pollyea on Emerging Therapies in Higher-Risk Myelodysplastic Syndrome

July 21st 2021

Daniel Pollyea, MD, MS, discusses emerging therapies in higher-risk myelodysplastic syndrome.

FDA Grants Breakthrough Therapy Designation to Venetoclax/Azacitidine for MDS

July 21st 2021

The FDA has granted a breakthrough therapy designation to the combination of venetoclax plus azacitidine for use in the treatment of adult patients with previously untreated, intermediate-, high-, and very high–risk myelodysplastic syndromes based on the revised International Prognostic Scoring System.

Ficlatuzumab Plus Chemotherapy Produces Promising Preliminary Clinical Activity in High-Risk AML

July 21st 2021

The investigational therapy ficlatuzumab in combination with cytarabine demonstrated encouraging clinical efficacy with favorable tolerability when used as a treatment in patients with high-risk acute myeloid leukemia.

Relapsed/Refractory DLBCL: Sequencing Therapy

July 20th 2021

Tycel Jovelle Phillips, MD, of the University of Michigan, comments on his preferences for treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and shares his expectations for sequencing with newer, novel approaches emerging in the field.

Belumosudil Represents Promising Newly-Approved Option for Chronic GVHD

July 20th 2021

Belumosudil induced clinically meaningful, durable responses in patients with chronic graft-versus-host-disease, irrespective of previous treatment received, severity of disease, and number of organs involved.

Safety of Loncastuximab Tesirine for Relapsed/Refractory DLBCL

July 20th 2021

Recommendations for mitigating and managing common treatment-related adverse events associated with loncastuximab tesirine based on safety data from LOTIS-2 and variables that may impact patient candidacy.

Bone Marrow Transplant for Patients With MF

July 20th 2021

Expert panelists review important disease-related and patient-related factors when considering bone marrow transplant in patients with primary myelofibrosis.

Jabbour on Tailoring Treatment With TKIs in CML and Ph+ ALL

July 19th 2021

Dr. Jabbour discusses the optimal use of ponatinib in chronic myeloid leukemia and data from the 2021 ASCO Annual Meeting with the combination of blinatumomab and ponatinib in Ph-positive acute lymphoblastic leukemia.

Ruxolitinib Data Published in NEJM Underscore ORR Benefit in Chronic GVHD, Irrespective of Organs Involved at Baseline

July 19th 2021

Ruxolitinib continued to result in a significant improvement in overall response rate compared with best available therapy in patients with steroid-refractory/dependent chronic graft-vs-host disease, regardless of the individual organs involved at baseline.

Outlook for CNS Lymphoma

July 19th 2021

David Rizzieri, MD, discusses new data from the ASCO 2021 Virtual Meeting regarding CNS lymphoma and treatment approaches in this setting.

DLBCL: Approaching CNS Prophylaxis

July 19th 2021

A panel of experts explain how they approach CNS prophylaxis in DLBCL.